Capabilities

Mammalian expression systems

GTP offers both IP-free and cutting-edge proprietary expression technologies to overcome expression challenges for recombinant proteins in mammalian cells. Our expert scientists have over 15 years of experience producing recombinant proteins and antibodies in mammalian cells.

Diverse mammalian cell technologies and structured development services to fit your recombinant protein project

Effective mammalian expression systems for recombinant proteins, monoclonal antibodies and antibody fragments

In most cases, mammalian cells are the optimal system to produce recombinant mammalian proteins. Their capacity for proper protein folding, for post-translational modifications, and for protein assembly are crucial to biological activity.

Over the last decade, the development of large molecule therapeutics has grown increasingly. This evolution has resulted in the emergence of more cost-effective and efficient mammalian systems. CHO is currently the main host for the commercial production of therapeutic proteins, including monoclonal antibodies (mAbs). The GTP team has sucessfully expressed a variety of recombinant proteins, monoclonal antibodies as well as antibody fragments in mammalian expression systems.

GTP's expertise in mammalian systems is directly linked to our longstanding experience with monoclonal antibodies and antibody fragments for therapeutic development programmes , virus-like particles for vaccine development, membrane target proteins for research studies…

Expert services for the expression of your protein in mammalian systems

Mammalian cells

For the successful production of your protein or antibody in mammalian cells, GTP provides a comprehensive range of services including:

  • Transient transfection or stable pools (HEK or CHO) production for early studies.
  • CHO cell line development.
  • Generation of cell banks (RCB & MCB).
  • Optimisation of cell culture parameters for high titer and/or product quality.

For early activity studies, our expert scientists have developed an efficient transient transfection platform in either CHO or HEK cells allowing the production of antibody quantities ranging from micrograms to grams. Thanks to our optimized expression conditions, we routinely achieve high expression yields for a variety of human and mouse antibodies.

For early stages of process development, we partner with technology companies to offer CHO cell line development and banking (Research and Master Cell Bank) services. Depending on your requirements and constraints, we select IP-free or proprietary technologies to develop high-titer mammalian cell lines.

GTP also offers complete upstream process development services for mammalian cells